Skip to main content
SpringerLink
Log in

Der Einsatz atypischer Neuroleptika bei therapieresistenten schizophrenen Psychosen

  • Conference paper
Atypische Neuroleptika

  • 22 Accesses

Zusammenfassung

Die Wirksamkeit einer neuroleptischen Pharmakotherapie in der Behandlung schizophrener Psychosen steht außer Zweifel. Dennoch gibt es eine nicht unbeträchtliche Zahl von Patienten, deren psychopathologische Auffälligkeiten durch eine solche Behandlung nicht oder nur unzureichend beeinflußt werden können. Die Gründe hierfür sind vielfältig. Es gibt nun Hinweise darauf, daß das bewährte, schon seit langem eingeführte atypische Neuroleptikum Clozapin bei einem Teil der Patienten, die auf eine Behandlung mit konventionellen Neuroleptika nicht ausreichend respondieren, dennoch wirksam ist. Dies läßt hoffen, daß vielleicht auch die neuen, teils gerade erst eingeführten oder kurz vor der Einführung stehenden Neuroleptika einen solchen Effekt haben könnten. Im folgenden soll ein aktueller Überblick zur Therapieresistenz unter konventionellen Neuroleptika und zum Stellenwert atypischer Neuroleptika bei der Behandlung therapieresistenter schizophrener Psychosen gegeben werden.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 84.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alvarez E, Barón J, Puigdemont José Soriano D, Masip C, Perez-Solá V (1997) Ten years’ experience with clozapine in treatment-resistant schizophrenic patients: factors indicating the therapeutic response. Eur Psychiatry 12 (Suppl 5): 343’346

    Article  Google Scholar 

  2. American Psychiatric Association (APA) (1997) Practice Guideline for the Treatment of Patients with Schizophrenia. APA, Washington, Dc

    Google Scholar 

  3. Andreasen NC (1993) Die Behandlung des therapieresistenten Patienten. In: Hinterhuber H, Kulhanek F, Fleischhacker WW, Neumann R (Hrsg) Prädiktoren und Therapieresistenz in der Psychiatrie. Vieweg, Braunschweig, S 82–96

    Chapter  Google Scholar 

  4. Bacher NM, Kaup BA (1996) Combining risperidone with standard neuroleptics for refractory schizophrenic patients. Am J Psychiatry 153:137

    PubMed  CAS  Google Scholar 

  5. Baldacchino AM, Stubbs JH, Nevison-Andrews D (1997) The use of olanzapine in noncompliant or treatment-resistant clozapine populations in hospital. Pharmac J 260: 207–209

    Google Scholar 

  6. Barnes TRE, McEvedy CJB (1996) Pharmacological treatment strategies in the nonresponsive schizophrenic patient. Int Clin Psychopharmacology 11: 67–71

    Article  Google Scholar 

  7. Baumann P (1993) Genetischer Polymorphismus des Metabolismus von Neuroleptika: klinische Relevanz? In: Möller HJ (Hrsg) Therapieresistenz unter Neuroleptikabehandlung. Springer, Wien New York, S 99–110

    Chapter  Google Scholar 

  8. Bender S, Eap CB (1998) Very high cytochrome P4501A2 activity and nonresponse to clozapine. Arch Gen Psychiatry 55:1048–1050

    Article  PubMed  CAS  Google Scholar 

  9. Bilder RM, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J, Ashtari M, Degreef G, Kane JM, Lieberman JA (1994) Cerebral morphometry and clozapine treatment in schizophrenia. J Clin Psychiatry 55 (Suppl B): 53–56

    PubMed  Google Scholar 

  10. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P, on behalf of the Risperidone Study Group (1998) Risperidone versus Clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 155: 499–504

    PubMed  CAS  Google Scholar 

  11. Breier A, Buchanan RW, Kirkpatrick B, Davis OR, Irish D, Summerfelt A, Carpenter WT Jr (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151: 20–26

    PubMed  CAS  Google Scholar 

  12. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, Kulhanek F, Liberman RP, Malm U, Midha KK (1990) Defining treatment refractoriness in schizophrenia. Schizophr Bull 16: 551–561

    PubMed  CAS  Google Scholar 

  13. Buckley P, Donenwirth K, Bayer K, Lys C, Ibrahim Z, Schulz S (1996) Risperidone for treatment-resistant schizophrenia: initial clinical experience in a state hospital. J Pharmacy Technology 12:271–275

    CAS  Google Scholar 

  14. Cavallaro C, Cordoba C, Smeraldi E (1995) A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Human Psychopharmacol 10: 231–234

    Article  Google Scholar 

  15. Chouinard G, Vainer JL, Belanger MC, Turnier L, Beaudry P, Roy JY, Miller R (1994) Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neurolepticinduced supersensitivity psychosis. Prog Neuropsychopharmacol Biol Psychiatry 18: 1129–1141

    Article  PubMed  CAS  Google Scholar 

  16. Christison GW, Kirch DG, Wyatt RJ (1991) When symptoms persist: choosing among alternative somatic treatments for schizophrenia. Schizophr Bull 17: 217–245

    PubMed  CAS  Google Scholar 

  17. Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbook R, Tuason V, Klerman G (1987) The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 7: 377–384

    Article  PubMed  CAS  Google Scholar 

  18. Clozapine Study Group (UK) (1993) The safety and efficacy of clozapine in severe treatmentresistant schizophrenic patients in the UK. Br J Psychiatry 163:150–154

    Article  Google Scholar 

  19. Conley RR, Buchanan RW (1997) Evaluation of treatment-resistant schizophrenia. Schizophr Bull 23: 663–674

    PubMed  CAS  Google Scholar 

  20. Conley RR, Carpenter WT Jr, Tamminga CA (1997) Time to clozapine response in a standardized trial. Am J Psychiatry 154:1243–1247

    PubMed  CAS  Google Scholar 

  21. Conley RR, Tamminga CA, Bartko JJ, Richardson C, Peszke M, Lingle J, Hegerty J, Love R, Gounaris C, Zaremba S (1998) Olanzapine compared with chlorpromazine in treatmentresistant schizophrenia. Am J Psychiatry 155: 914–920

    PubMed  CAS  Google Scholar 

  22. Daniel DG, Whitcomb SR (1998) Treatment of the refractory schizophrenic patient. J Clin Psychiatry 59 (Suppl 1): 13–19

    PubMed  Google Scholar 

  23. Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, Williams TS (1996) Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study. Am J Psychiatry 153: 417–419

    PubMed  CAS  Google Scholar 

  24. Davis JM, Schaffer CB, Killian GA, Kinard C, Chan C (1980) Important issues in the drug treatment of schizophrenia. Schizophr Bull 6: 70–87

    PubMed  CAS  Google Scholar 

  25. Deister A (1995) Therapieresistenz: Definition, Häufigkeit und therapeutische Möglichkeiten. In: Naber D, Müller-Spahn F (Hrsg) Clozapin: Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer, Berlin Heidelberg New York Tokyo, S 9–18

    Chapter  Google Scholar 

  26. Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) (Hrsg) (1998) Praxisleitlinien in Psychiatrie und Psychotherapie (Redaktion: Gaebel W, Falkai P), Bd 1: Behandlungsleitlinie Schizophrenie, Steinkopff, Darmstadt

    Google Scholar 

  27. Dossenbach M, Belmaker HP, Elizur A, Goldin V, Munitz H, Schneidman M, Shoshani D (1997) Olanzapine in patients with clozapine treatment failure. Biol Psychiatry 42: 231S

    Article  Google Scholar 

  28. Evans EG (1995) Risperidone in institutionalized psychotic patients unresponsive to conventional antipsychotic agents. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association. Miami, Fla: 187 (zitiert nach Daniel und Whitcomb 1998)

    Google Scholar 

  29. Falkai P, Bogerts B, Klieser E, Waters H, Schlüter U, Mooren I (1993) Quantitativ-morphometrische Befunde im CT bei Neuroleptika-Nonrespondern. In: Möller HJ (Hrsg) Therapieresistenz unter Neuroleptikabehandlung. Springer, Wien New York, S 37–48

    Chapter  Google Scholar 

  30. Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, Honer WG (1998) An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 31: 25–29

    Article  PubMed  CAS  Google Scholar 

  31. Frances A, Docherty JP, Kahn DA (Hrsg) (1996) The Expert Consensus Guidelines Series. Treatment of Schizophrenia. J Clin Psychiatry 57 (Suppl 12B): 1–58

    Google Scholar 

  32. Fujii DE, Ahmed I, Jokumsen M, Compton JM (1997) The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients. J Neuropsychiatry Clin Neurosci 9: 240–245

    PubMed  CAS  Google Scholar 

  33. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34: 702–712

    Article  PubMed  CAS  Google Scholar 

  34. Harada T, Otsuki S, Sato M, Wake A, Fujiwara Y, Kashihara K, Fukuda K (1987) Effectivity of zotepine in refractory psychoses: possible relationship between zotepine and non-dopamine psychosis. Pharmacopsychiatry 20 (1 Spec No): 47–51

    Article  PubMed  CAS  Google Scholar 

  35. Harada T, Otsuki S, Fujiwara Y (1991) Wirksamkeit von Zotepin bei therapieresistenten Psychosen: eine offene, multizentrische Studie in acht psychiatrischen Kliniken. Fortschr Neurol Psychiat 59 (Suppl 1): 41–44

    Article  PubMed  Google Scholar 

  36. Jalenques I (1996) Drug-resistant schizophrenia: treatment options. CNS Drugs 5: 8–23

    Article  CAS  Google Scholar 

  37. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA (1995) Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Ser 46: 801–806

    CAS  Google Scholar 

  38. Kane J, Honigfeld G, Singer J, Meltzer H and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45: 789–796

    Article  PubMed  CAS  Google Scholar 

  39. Keefe RSE, Lobel DS, Mohs RC, Silverman JM, Harvey PD, Davidson M, Losonczy MF, Davis KL (1991) Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia undifferentiated schizophrenia, and state-independent negative symptoms. Schizophr Res 4: 71–79

    Article  PubMed  CAS  Google Scholar 

  40. Klieser E, Schöneil H (1990) Klinisch-pharmakologische Studie zur Behandlung schizophrener Minussymptomatik. In: Möller HJ, Pelzer E (Hrsg) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin New York, S 217–222

    Chapter  Google Scholar 

  41. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrichs K (1995) Randomized, doubleblind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 15 (Suppl 1): 45S–51S

    PubMed  CAS  Google Scholar 

  42. Konrad C, Schormair C, Knickelbein U, Ophaus P, Eikelmann B (1997) Risperidone and clozapine in pharmaco-resistant schizophrenia. Pharmacopsychiatry 30:190

    Google Scholar 

  43. Kronig MH, Loebel AD et al. (1994) Risperidone in treatment-resistant schizophrenia and schizoaffective patients. In: Syllabus of the APA 46th Institute of Hospital and Community Psychiatry. San Diego, Calif, Abstract 72 (zitiert nach Daniel und Whitcomb 1998)

    Google Scholar 

  44. Kuoppasalmi K, Rimon R, Naukkarinen H, Lang S, Sandqvist A, Leinonen E (1993) The use of clozapine in treatment-refractory schizophrenia. Schizophr Res 10:29–32

    Article  PubMed  CAS  Google Scholar 

  45. Lacey RL, Preskorn SH, Jerkovich GS (1995) Is risperidone a substitute for clozapine for patients who do not respond to neuroleptics? Am J Psychiatry 152:1401

    PubMed  CAS  Google Scholar 

  46. Launer MA (1998) High-dose olanzapine in treatment-resistant schizophrenia. Schizophr Res 29:149–150

    Article  Google Scholar 

  47. Lieberman JA, Jody D, Alvir JMJ, Borenstein M, Mayerhoff DI, Geisler S, Szymanski S, Gonzales A, Bogerts B, Ashtari M (1991) Negative symptoms in schizophrenia: relationship to positive symptoms and outcome. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, S 109–125

    Chapter  Google Scholar 

  48. Lieberman JA, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S (1998) The development of treatment resistance in patients with schizophrenia: a clinical and pathophysiological perspective. J Clin Psychopharmacol 18 (Suppl 1): 20S–24S

    PubMed  CAS  Google Scholar 

  49. Lindenmayer JP, Grochowski S, Magubat L (1994) Clozapine effects on positive and negative symptoms: a six-month trial in treatment-refractory schizophrenics. Clin Psychopharmacol 14:201–204

    Article  CAS  Google Scholar 

  50. Lindenmayer JP,Iskander A, Park M,Apergi FS, Czobor P, Smith R, Allen D (1998) Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 10: 521–527

    Article  Google Scholar 

  51. Martin J, Gómez JC, García-Bernado E, Cuesta M, Alvarez E, Gurpegui M, and the Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia (1997) Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 58: 479–483

    Article  PubMed  CAS  Google Scholar 

  52. May PRA, Dencker SJ, Hubbard JW, Midha KK, Liberman RP (1988) Ein sytematischer Ansatz zur Therapieresistenz schizophrener Erkrankungen. In: Bender W, Dencker SJ, Kulhanek F (Hrsg) Schizophrene Erkrankungen: Therapie, Therapieresistenz — eine Standortbestimmung. Vieweg, Braunschweig, S 133–150

    Google Scholar 

  53. Meltzer HY (1995) Multiple-outcome criteria in schizophrenia: an overview of outcome with clozapine. Eur Psychiatry 10 (Suppl 1): 19–25

    Article  Google Scholar 

  54. Meltzer HY (1997) Treatment-resistant schizophrenia ñ the role of clozapine. Curr Med Res Opin 14:1–20

    Article  PubMed  CAS  Google Scholar 

  55. Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B (1997) Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study. Pharmacopsychiatry 30:35–42

    Article  PubMed  CAS  Google Scholar 

  56. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC (1994) Clozapineís effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 35: 8–15

    Article  PubMed  CAS  Google Scholar 

  57. Möller HJ (1993) Vorhersage des Therapieerfolges schizophrener Patienten unter neuroleptischer Akutbehandlung. In: Möller HJ (Hrsg) Therapieresistenz unter Neuroleptikabehandlung. Springer, Wien New York, S 1–12

    Chapter  Google Scholar 

  58. Naber D, Holzbach R, Perro C, Hippius H (1992) Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry 160 (Suppl 17): 54–59

    Google Scholar 

  59. Naber D, Krausz M, Lambert M, Bender S (1999) Refractory schizophrenia. In: Lader M, Naber D (eds) Difficult clinical problems in psychiatry. Martin Dunitz Publishers 3–22

    Google Scholar 

  60. Pajonk F, Naber D, Hippius H (1997) Alternativen zum Clozapin? Klinische Erfahrungen mit Risperidon. In: Naber D, Müller-Spahn F (Hrsg) Clozapin: Pharmakologie und Klinik eines atypischen Neuroleptikums. Springer, Berlin Heidelberg New York Tokyo, S 89–104

    Google Scholar 

  61. Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH (1992) Clinical and biologic response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatry 49: 345–353

    Article  PubMed  CAS  Google Scholar 

  62. Prakash A, Lamb HM (1998) Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the mangement of schizophrenia. CNS Drugs 9: 153–175

    Article  CAS  Google Scholar 

  63. Raza A, Ettinger T, Sharif ZA et al. (1995) A comparison of the efficacy of clozapine and risperidone in treatment-refractory schizophrenia. In: New Research Program and Abstracts of the 148th Annual Meeting of the American Psychiatric Association. Miami, Fla: 117 (zitiert nach Daniel und Whitcomb 1998)

    Google Scholar 

  64. Robinson D, Lieberman JA, Sheitman B, Alvir JAJ, Kane J (1996) A pilot study of atypical antipsychotic agents in first episode schizophrenia. Presented at the 35th Annual Meeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico (zitiert nach Lieberman et al. 1998)

    Google Scholar 

  65. Schall U, Catts SV, Chaturvedi S, Liebert B, Redenbach J, Karayanidis F, Ward PB (1998) The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: neuro-psychology and event-related potential measures. Int J Neuropsychopharmacol 1:19–29

    Article  PubMed  CAS  Google Scholar 

  66. Schüßler G, Müller-Oerlinghausen B, Schmidt LG (1988) Vergleich einer höher dosierten Haloperidoltherapie mit einer Perazinstandardtherapie bei akut schizophrenen Patienten. In: Helmchen H, Hippius H, Tölle R (Hrsg) Therapie mit Neuroleptika ñ Perazin. Thieme, Stuttgart New York: S 40–50

    Google Scholar 

  67. Sheitman BB, Lindgren JC, Early J, Sved M (1997) High-dose olanzapine for treatment-refractory schizophrenia. Am J Psychiatry 154:1626

    PubMed  CAS  Google Scholar 

  68. Small JG, Milstein V, Marhenke JD, Hall DD, Kellams JJ (1987) Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity, and treatment-resistant psychosis. J Clin Psychiatry 48: 263–267

    PubMed  CAS  Google Scholar 

  69. Small JG, Miller MJ, Klapper MH et al. (1993) Risperidone versus clozapine in resistant schizophrenia. In: Programs and Abstracts of the 146th Annual Meeting of the American Psychiatric Association. San Francisco, Calif: 241 (zitiert nach Daniel und Whitcomb 1998)

    Google Scholar 

  70. Smith RC, Chua JW, Lipetsker R, Bhattacharyya A (1996) Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. J Clin Psychiatry 57: 460–466

    Article  PubMed  CAS  Google Scholar 

  71. Szymanski S, Masiar S, Mayerhoff D, Loebel A, Geisler S, Pollack S, Kane J, Lieberman J (1994) Clozapine response in treatment-refractory first-episode schizophrenia. Biol Psychiatry 35: 278–280

    Article  PubMed  CAS  Google Scholar 

  72. Tandon R, Goldman R, DeQuardo JR, Goldman M, Perez M, Jibson M (1993) Positive and negative symptoms covary during treatment in schizophrenia. J Psychiatr Res 27: 341–347

    Article  Google Scholar 

  73. Tanner TB, Ganguli R, Reddy R, Allen M, Field K (1995) Risperidone for treatment-refractory schizophrenia. Am J Psychiatry 152:1233

    PubMed  CAS  Google Scholar 

  74. Thomas SG, Labbate LA (1998) Management of treatment-resistant schizophrenia with olanzapine. Can J Psychiatry 43:195–196

    PubMed  CAS  Google Scholar 

  75. Van Kammen DP, Schooler N (1990) Are biochemical markers for treatment-resistant schizophrenia state dependent or traits? Clin Neuropharmacol 13 (Suppl 1): S16–S28

    Article  PubMed  Google Scholar 

  76. Wimmer P, Belmaker RH, Schneidman M, Treves I, Sapir M, Dossenbach M (1998) Treatment failure with risperidone: can olanzapine be an alternative therapy? Schizophr Res 29:148

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Psychiatrie und Psychotherapie, Universität GH Essen, Virchowstr. 174, 45147, Essen, Deutschland

    Prof. Dr. M. Gastpar (Ärztlicher Direktor)

Authors
  1. Prof. Dr. M. Gastpar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Bender
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Psychiatrische Klinik und Poliklinik mit Konsiliardienst, Großhadern, Klinikum Innenstadt, Nußbaumstraße 7, D-80336, München, Deutschland

    Hans-Jürgen Möller  & Norbert Müller  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt

About this paper

Cite this paper

Gastpar, M., Bender, S. (1999). Der Einsatz atypischer Neuroleptika bei therapieresistenten schizophrenen Psychosen. In: Möller, HJ., Müller, N. (eds) Atypische Neuroleptika. Steinkopff. https://doi.org/10.1007/978-3-642-93709-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-93709-5_4

  • Publisher Name: Steinkopff

  • Print ISBN: 978-3-7985-1179-8

  • Online ISBN: 978-3-642-93709-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation